Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Santhera Closes License-Back Deal with Takeda

Published: Friday, September 27, 2013
Last Updated: Friday, September 27, 2013
Bookmark and Share
Agreement with Takeda to license back previously granted European rights to Catena® in DMD.

Santhera Pharmaceuticals has announced that it has reached an agreement with Takeda to license back previously granted European rights to Catena® (INN: idebenone) in Duchenne Muscular Dystrophy (DMD).

In a back-loaded deal, Santhera regains European commercialization rights for Catena®. The drug is currently being investigated in a Phase III study in DMD conducted in Europe and in the USA.

In 2007, Takeda Pharmaceutical Company Limited (TSE: 4502, "Takeda") acquired the exclusive marketing rights in Europe and Switzerland for Catena® for the treatment of DMD.

Under the agreement reached, Santhera licenses back all such previously granted rights to increase its strategic flexibility. In return, Takeda is eligible to obtain a percentage from future licensing and/or sales income generated by Santhera in DMD.

In addition, Santhera has obtained the right to cross-reference Takeda's idebenone data for regulatory use in any indication in any territory.

If Santhera makes use of such cross-reference right, Takeda is eligible to obtain a percentage from future licensing and/or sales income generated by Santhera in such indications.

Lastly, both companies agreed to terminate a similar agreement for Friedreich's Ataxia signed in 2005 and Santhera's previously disclosed contingent liability of EUR 1 million payable to Takeda has been waived.

Takeda is eligible to receive Euro 1 million as a percentage from future income generated by Santhera to offset this waiver.

"The agreement we reached today with Takeda clearly increases our strategic flexibility. Potential licensees interested in Catena® in DMD can now be offered global rights to this program", commented Thomas Meier, CEO of Santhera.

Meier continued, "The ongoing DELOS study has recently passed a futility analysis and we expect to report top-line data from the first cohort of patients in this study in the second quarter of 2014. Today's agreement with Takeda also grants us right of cross-reference to certain data which may be needed for any regulatory filings for indications currently being developed or which may be developed in the future."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Santhera Starts Phase III Study with Raxone in DMD
The trial will assess the efficacy of Raxone in slowing the rate of respiratory function decline in Duchenne muscular dystrophy (DMD) patients receiving concomitant glucocorticoids.
Wednesday, September 28, 2016
Santhera Reports Financial Results
Results for the first half year and transitions towards product company.
Tuesday, September 15, 2015
Santhera Receives European Marketing Authorization for Raxone®
First approved treatment for LHON and first approved treatment for a mitochondrial disease.
Thursday, September 10, 2015
Santhera Receives Rare Pediatric Disease Designation from FDA
FDA has granted designation for idebenone for the treatment of Duchenne Muscular Dystrophy.
Tuesday, August 25, 2015
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Tuesday, July 21, 2015
CHMP Recommends Granting a Marketing Authorization for Santhera's Raxone®
Raxone® (idebenone) for the treatment of visual impairment in adolescent and adult patients with LHON.
Friday, June 26, 2015
Santhera Update on Pre-NDA Meeting with FDA
Company plans to submit a New Drug Application for Raxone®/Catena® (idebenone) in Duchenne Muscular Dystrophy.
Tuesday, June 16, 2015
Santhera's Positive Phase III Trial in DMD Patients Published in The Lancet
First successful Phase III trial in DMD shows Raxone®/Catena® preserves respiratory function.
Thursday, April 23, 2015
Santhera Receives FDA Fast Track Designation for Raxone®/Catena®
Fast Track designation for the treatment of Duchenne Muscular Dystrophy.
Friday, April 10, 2015
Santhera Repositions Omigapil in Congenital Muscular Dystrophy
Company initiates clinical development program with public-private partners.
Thursday, July 17, 2014
Santhera Announces Successful Outcome of Phase III Study with Catena®/Raxone® in DMD
Positive outcome indicates that Catena®/Raxone® can mitigate respiratory weakness and dysfunction.
Tuesday, May 27, 2014
Santhera Secures Exclusive Rights from NIH
Santhera has obtained the exclusive rights to the use patent for idebenone in ppMS granted in the USA.
Monday, June 10, 2013
Santhera and Ipsen Renegotiate Fipamezole Licensing Agreement
Santhera regains worldwide rights for fipamezole.
Tuesday, January 24, 2012
Santhera Obtains US Patent for Use of Catena® in the Treatment of Muscular Dystrophies
The patent in the United States is supplemented by a similar patent in the European Union granted in 2010.
Wednesday, August 24, 2011
Data from Santhera's RHODOS Study to Be Presented at the European Neurological Society 2011 Meeting
Results from the RHODOS study evaluate the efficacy of Catena® in Leber Hereditary Optic Neuropathy.
Tuesday, June 07, 2011
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Modified Yeast Shows Plant Response to Key Hormone
Researchers have developed a toolkit based on modified yeast to determine plant responses to auxin.
Adipose Tissue Secretes Factors That Activate Metabolism
Study finds brown adipose tissue secretes signalling factors that activates metabolism of fat and carbohydrates.
Antibiotic Resistant Bacteria In America's Water System
Antibiotic resistant bacteria live inside drinking water distribution systems blamed for rising healthcare costs.
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
Ancient Eggshell Protein Breaks Through DNA Time Barrier
Fossil proteins from a 3.8million year-old eggshell have been identifed, suggests proteins could give insight into evolutionary tree.
Monkeys Protected by Zika DNA Vaccine
Experimental Zika virus DNA vaccines successfully protected monkeys against Zika infection.
Nanosensors Could Determine Tumours’ Ability to Remodel Tissue
Researchers design nanosensors that can profile tumours, focusing on protease levels.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!